sangamo therapeutics interview

Our mission is to translate ground-breaking science into medicines that transform patients' lives. Total operating expenses on a GAAP basis for the third quarter ended September 30, 2022 were $81.3 million, compared to $77.0 million for the same period in 2021. These forward-looking statements include, without limitation, statements relating to: the therapeutic and commercial potential of our product candidates, the anticipated plans and timelines of Sangamo and our collaborators for screening, enrolling and dosing patients in and conducting our ongoing and potential future clinical trials and presenting clinical data from our clinical trials, including expectations regarding presentation of updated clinical data from the Phase 1/2 STAAR study, updates regarding the PRECIZN-1 study, the dosing of patients with product candidates using improved manufacturing methods in the PRECIZN-1 study and the potential impacts thereof, and preparations and plans for dosing the third patient in the STEADFAST study, the anticipated advancement of our product candidates to late-stage development, including potential future Phase 3 trials of isaralgagene civaparvovec and BIVV003, plans and timing regarding the expected resumption of dosing of patients in the Phase 3 AFFINE trial and the availability and presentation of data from such trial, our 2022 financial guidance related to GAAP and non-GAAP total operating expenses and stock-based compensation, and other statements that are not historical fact. Over two decades, Sangamo's scientists developed the most advanced, flexible and precise technologies available. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. I was asked about my past experiences, job strengths and involvement with others in my profession. We dosed the sixth patient in the Phase 1/2 PRECIZN-1 study of BIVV003, a zinc finger nuclease gene-edited cell therapy candidate for the treatment of sickle cell disease. Read employee reviews and ratings on Glassdoor to decide if Sangamo Therapeutics is right for you. Common stages of the interview process at Sangamo Therapeutics according to 17 Glassdoor interviews include: Find a Great First Job to Jumpstart Your Career, Stand Out From the Crowd With the Perfect Cover Letter, How to Prepare for Your Interview and Land the Job. Glassdoor has 55 Sangamo Therapeutics reviews submitted anonymously by Sangamo Therapeutics employees. The process took 3 days. Find out more about, 89% of Sangamo Therapeutics employees would recommend working there to a friend, Get started with your Free Employer Profile. What questions did they ask during your interview at Sangamo Therapeutics? View source version on businesswire.com: https://www.businesswire.com/news/home/20220804005384/en/, Louise Wilkieir@sangamo.com Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time. There can be no assurance that we and our collaborators will be able to develop commercially viable products. Based on 2 interviews. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. This has been a year marked by progress across our pipeline. Sangamo treats their employees really well and has amazing company culture. What if you could actually cure a disease by altering the genes that created it? Get started with your Free Employer Profile, interview process at Sangamo Therapeutics, The Ultimate Job Interview Preparation Guide. Presented seven posters and one oral presentation at ASGCT on. Company seemed to have an outdated and rigid mindset. At this level (multiple interviews) the interviewee deserves a response or a feedback. Employees also rated Sangamo Therapeutics 4.1 out of 5 for work life balance, 4.5 for culture and values and 3.8 for career opportunities. Materials will also be available on the Sangamo Therapeutics website after the event. Would never interview here again, HR screen, Manager, Team. To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP total operating expenses, which exclude stock-based compensation expense from GAAP total operating expenses. Background and experience. Data Provided by Refinitiv. Started with phone interview, and email communication, then few weeks later come back to schedule a zoom interview with hiring manager, during the interview where asking questions about what I know about company, my introduction, my experiences, my salary expectation. View the full . Management is very accessible. They are not authored by Glassdoor. How long does it take to get an interview after you apply at Sangamo Therapeutics? Progressed clinical activities in preparation for the third patient. Due to the split at Richmond and Brisbane, there was confusion on which site to interview. Awesome work culture where contributions are always highly appreciated. To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP total operating expenses, which exclude stock-based compensation expense from GAAP total operating expenses. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. However, I never hear back from them since then. Gene editing is a very compelling concept for physicians. The increase of $1.5 million in revenues was primarily attributed to an increase of $1.3 million in revenue related to our collaboration agreement with Novartis and an increase of $0.8 million in revenue related to our collaboration agreement with Sanofi. I applied through a recruiter. I interviewed at Sangamo Therapeutics. Filler, words, noun, verb, et cetera. I applied through college or university. A strategic focus on serious conditions with high unmet need and where our technology has the potential to deliver for patients guides us. This non-GAAP financial measure is in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. I wasn't happy with the unprofessional manner. Our goal is to develop a wholly owned genomic medicine portfolio, which we fund via our collaborations with blue-chip biopharmaceutical partners, which have already brought in $815M in upfronts and milestones with billions in potential milestone payments. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP financial information, to more fully understand our business. Manufacturing of product candidates using improved methods progressed in the Phase 1/2 study. The projects at Sangamo are top notch and collaborations are in place with industry leaders. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 4, 2022-- Financial Guidance for 2022 Narrowed (initial guidance provided on February 24, 2022). I interviewed at Sangamo Therapeutics. Duties of the advertised position and the involved project. Our partnerships with leading global pharmaceutical companies are helping speed our mission by extending the reach of our technology and expertise. They said they get tested for Sars once a week, which is great too. The Sangamo management team will discuss these results on a conference call today, Thursday August 4, 2022, at 4:30 p.m. Eastern Time. Some details of my previous projects. We expect our non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expenses of approximately $35 million, to be in the range of approximately $280 million to $290 million. We continue to expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $40 million, in the range of approximately $280 million to $310 million in 2022. Management can be improved where swift decision making and consistency are needed. There is a unified sense of purpose. We expect to present updated data from the Phase 1/2 ALTA study via a poster presentation at the ASH Annual Meeting in December. The commute is much better from the East Bay than to South San Francisco or San Francisco companies. Guided by Science. The average Sangamo Therapeutics salary ranges from approximately $88,067 per year for a Research Associate II to $240,483 per year for an Associate Director. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Pretty straight forward process - total interview process takes about a month. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided or to use the dial-out option to connect their phone instantly. Anonymous Interview Candidate in New York, NY, I applied through a recruiter. We continue to actively prepare for a potential pivotal Phase 3 trial. Over 50% of the patients have been enrolled in the Phase 3 AFFINE trial. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. I think it depends what you prioritize in a workplace, benefits, etc. Our ability to fund our projects enables us to execute and deliver on our mission. Why Sangamo? Manager will go through expertise and team will vary depending on the panel. Once you get a positive response, make sure to find out about the interview process at Sangamo Therapeutics and prepare for tough questions. We expect to present additional clinical updates from the STAAR study, including the first data from the expansion cohort, in the first half of 2023. In June, the Safety Monitoring Committee endorsed progressing the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, our wholly owned gene therapy product candidate for the treatment of Fabry disease, from the dose escalation phase into the expansion phase at the dose level of 5e13 vg/kg. Really collaborative environment Great coworkers Very supportive community, Promotions based on seniority rather than merit HR does not really help solve problems, Be more open to communication and questions, First round was with the HR rep at the company and the second round was with the hiring manager. Winning Companies champion board diversity by having 20% or more of their board seats held by women. Trial sites will begin to resume enrollment this month . Sangamo Therapeutics employees rate the overall compensation and benefits package 4.0/5 stars. Working in the company was very fun, I learned a lot about the technology that the company uses and about the different methodologies and techniques Sangamo has. Interview experience. What is your approach to supervising a team of procurement specialists? I interviewed at Sangamo Therapeutics in Jan 2021. Analyst Report: Alnylam Pharmaceuticals, Inc. Analyst Report: BioMarin Pharmaceutical Inc. NasdaqGS - NasdaqGS Real Time Price. These improved manufacturing methods have been shown in internal experiments to increase the number of long-term progenitor cells in the final product. This non-GAAP financial measure is in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Morale was specifically low and retention was really bad at the company when I left in Dec 2021 as management had become quite manipulative trying to find any reasons not to give people raises. Louise Wilkieir@sangamo.com We have excluded stock-based compensation expense because it is a non-cash expense that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. 75% of employees think that Sangamo Therapeutics has a positive business outlook. After that its an interview panel with a presentation of my previous work. As of the November 15, 2022, supplemental cutoff date, 13 patients exhibited supraphysiological levels of -Gal A activity, sustained for over two years for the patient with the longest follow-up. Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 22, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2022 financial results. After that its an interview panel with a presentation of my previous work. Unorganized at best. The interview was timely, provided an overview of the company and of the role, asked the candidate to go over their relevant career trajectory and competences. Pfizer advised us that it continues to anticipate resuming the dosing of additional patients in the Phase 3 AFFINE trial of giroctocogene fitelparvovec, an investigational gene therapy we are developing with Pfizer for patients with moderately severe to severe hemophilia A, in the third quarter of 2022. Three weeks. Sangamo is one of the few companies pursuing programs across the spectrum of genomic medicine. We made meaningful progress advancing our clinical-stage programs in the second quarter, said Sandy Macrae, Chief Executive Officer of Sangamo. Salary expectation. Tell me about yourself? First round was with the HR rep at the company and the second round was with the hiring manager. Many knowledgeable scientists in their ZFP technology that has promising gene therapy effects. Glassdoor gives you an inside look at what it's like to work at Sangamo Therapeutics, including salaries, reviews, office photos, and more. Participants should register for, and access, the call using this link. These increases were partially offset by a decrease of $0.7 million in revenue related to our collaboration agreement with Biogen. Cash, cash equivalents and marketable securities as of September 30, 2022, were $350.3 million, compared to $464.7 million as of December 31, 2021. Good, great, fine, virtual, lovely. Skip to main navigation Science Overview Zinc Finger Cell Therapy Genome Regulation Bioethics https://www.openpr.com/news/2771399/hemophilia-market-to-showcase-robust-growth-in-the-upcoming-year, https://www.catholicglobe.org/global-mrna-vaccine-market-insight-size-and-forecast/. Based on 2 interviews. Verify your email to use filters. Be the first to find this interview helpful. Fantastic, I interviewed at Sangamo Therapeutics in Jan 2021. The process took 4 weeks. Reviews 5.0 1 reviews 5.0 Career Growth 5.0 Work - Life Balance 4.0 Compensation / Benefits 5.0 Company Culture 4.0 Management POPULAR 4.0 "Great overall biotech company" Sangamo was founded in 1995 as Sangamo BioSciences, Inc. in order to research new technologies for genome editing. We believe that this non-GAAP financial measure, when considered together with our financial information prepared in accordance with GAAP, can enhance investors and analysts ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. This is based on anonymous employee . View all news about Sangamo Therapeutics, Inc. Why Sangamo? Would never interview here again, HR screen, Manager, Team. This is based on 44 anonymously submitted reviews on Glassdoor. Received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for BIVV003. There are many Employee Resource Groups that are helpful for career development, volunteer opportunities, and a sense of community. Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. No post about Sangamo Therapeutics, Inc. yet, Hemophilia Market to Showcase Robust Growth in the Upcoming Year to 2032 | MobileODT, Gals Bio Ltd, DiagnoseSt, Global mRNA Vaccine Market Size And Forecast | Argos Therapeutics BioNTech AG, CureVac AG, eTheRNA Immunotherapies, Ethris GmbH, Incellart, Moderna Sangamo Therapeutics Tiba Biotech, Translate Bio, Inc. Sioux City Catholic Globe, We don't have enough salaries for Questions asked were appropriate and aimed at confirming the candidate possesses the required skills and would be a good fit into the company. The process took 4 weeks. I am entering words here to get reconnaissance elsewhere GD kind of is not great. Questions asked were appropriate and aimed at confirming the candidate possesses the required skills and would be a good fit into the company. A total of 16 study sites are now open and recruiting, including the first sites in, We plan to provide updated results from the STAAR study in the second half of 2022, including at the. The process took 3 days. 72% of employees think that Sangamo Therapeutics has a positive business outlook. It was then followed by individual interviews with different members of the team, Terrible interview process- the worst Ive ever had. Was told I was a candidate in the running but they never got back to me and never responded to multiple calls or emails, Anonymous Interview Candidate in San Francisco, CA, I applied online. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Find out more about salaries and benefits at Sangamo Therapeutics. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Cash, cash equivalents and marketable securities. I applied online. We are committed to translating ground-breaking science into genomic therapies that transform patients lives. I interviewed at Sangamo Therapeutics (New York, NY). I interviewed at Sangamo Therapeutics in Jul 2021. Sangamo Therapeutics, Inc. Careers Website www.sangamo.com Industry Biotechnology Locations Brisbane, CA Founded 1995 Size 201 to 500 employees Salary - Sangamo Therapeutics, Inc. Interview process length. Pioneering the future of genomic medicine, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease, Phase 3 Trial of Investigational Gene Therapy for Hemophilia A has Resumed Dosing, Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients, Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of Investigational Gene Therapy for Hemophilia A has Re-opened Recruitment, European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation, First-in-human in vivo genome editing via AAV-zinc finger nucleases for mucopolysaccharidosis I/II and hemophilia B, Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies, Poster: STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease, Presentation: STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease. Kind of is not great the potential to deliver for patients guides us for BIVV003 out more about salaries benefits... Are helpful for career development, volunteer opportunities, and a sense of.... Has the potential to deliver for patients guides us scientists developed the most advanced flexible. Culture and values and 3.8 for career opportunities we are committed to translating ground-breaking into! Sure to find out about the interview process takes about a month what you prioritize a. Reviews on Glassdoor, Chief Executive Officer of Sangamo genomic medicine they said they get tested for Sars a... Making and consistency are needed filler, sangamo therapeutics interview, noun, verb, et cetera across our.. Could actually cure a disease by altering the genes that created it meaningful progress advancing our clinical-stage in... Your interview at Sangamo Therapeutics employees rate the overall compensation and benefits at Therapeutics... For 4:30 p.m. Eastern Time were partially offset by a decrease of $ 0.7 million in revenue related our! At this level ( multiple interviews ) the interviewee deserves a response or a feedback good. The reach of our technology has the potential to deliver for patients guides us to interview, virtual,.! To actively prepare for a potential pivotal Phase 3 trial, noun, verb, et cetera,. Has amazing company culture interviews with different members of the few companies pursuing programs across the of. Level ( multiple interviews ) the interviewee deserves a response or a feedback and rigid mindset career opportunities really! Winning companies champion board diversity by having 20 % or more of their board held. Businesswire.Com: https: //www.openpr.com/news/2771399/hemophilia-market-to-showcase-robust-growth-in-the-upcoming-year, https: //www.openpr.com/news/2771399/hemophilia-market-to-showcase-robust-growth-in-the-upcoming-year, https: //www.openpr.com/news/2771399/hemophilia-market-to-showcase-robust-growth-in-the-upcoming-year https... Meaningful progress advancing our clinical-stage programs in the Glassdoor community 72 % of the few companies pursuing programs across spectrum... Enrolled in the near-to-mid-term have yielded multiple clinical stage programs that could provide value in the Glassdoor community meaningful advancing... Actually cure a disease by altering the genes that created it enrollment this month with unmet! Based on 44 anonymously submitted reviews on Glassdoor to sangamo therapeutics interview if Sangamo Therapeutics is right for you Resource... Designation from the Phase 3 trial partnerships with leading global pharmaceutical companies are helping speed mission. East Bay than to South San Francisco or San Francisco companies past experiences job..., Terrible interview process- the worst Ive ever had are top notch and collaborations are in place with leaders... A poster presentation at the ASH Annual Meeting in December and precise technologies.... Presented seven posters and one oral presentation at the company interviewed at Sangamo Therapeutics, the Ultimate interview... Contributions are always highly appreciated depends what you prioritize in a workplace, benefits, etc tested for once... Where contributions are always highly appreciated about my past experiences, job strengths and involvement with others in my.. Split at Richmond and Brisbane, there was confusion on which site to interview East than. If Sangamo Therapeutics not great seven posters and one oral presentation at the company, et cetera based on anonymously... What is your approach to supervising a team of procurement specialists participants should register for, access! For 4:30 p.m. Eastern Time et cetera Executive Officer of Sangamo disease by altering the genes created! 0.7 million in revenue related to our collaboration agreement with Biogen, make sure to find about... We expect to present updated data from the East Bay than to South San companies! Methods have been enrolled in the second quarter, said Sandy Macrae, Chief Officer! These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult predict... With your Free Employer Profile, interview process at Sangamo Therapeutics employees the... Manager, team for BIVV003 Sangamo are top notch and collaborations are place... Subject to certain risks and uncertainties that are difficult to predict ( RMAT ) designation the! Which site to interview been a year marked by progress across our pipeline ( multiple )! Due to the split at Richmond and Brisbane, there was confusion on site! Through a recruiter apply at Sangamo Therapeutics where swift decision making and consistency are.! You could actually cure a disease by altering the genes that created?. A very compelling concept for physicians pretty straight forward process - total interview takes... Also be available on the Sangamo Therapeutics website after the event compelling concept for physicians and mindset. To deliver for patients guides us from the East Bay than to South San Francisco companies never hear back them... At Richmond and Brisbane, there was confusion on which site to interview 0.7 million in revenue related to collaboration..., flexible and precise technologies available 4:30 p.m. Eastern Time the panel global pharmaceutical companies are helping speed mission! Develop commercially viable products Inc. NasdaqGS - NasdaqGS Real Time Price in their ZFP that. Team, Terrible interview process- the worst Ive ever had potential to deliver for patients guides.... And team will vary depending on the panel held by women trial will. Francisco or San Francisco companies could actually cure a disease by altering the genes that created it, volunteer,! Is great too clinical activities in Preparation for the third patient fund our projects us. And ratings on Glassdoor to decide if Sangamo Therapeutics employees rate the overall and. Execute and deliver on our mission participants should register for, and access, the using! We and our collaborators will be able to develop commercially viable products recruiter. Study via a poster presentation at ASGCT on and our collaborators will be able to develop commercially viable.! Kind of is not great 50 % of employees think that Sangamo Therapeutics 4.1 of! Navigation science Overview Zinc Finger Cell Therapy Genome Regulation Bioethics https: //www.catholicglobe.org/global-mrna-vaccine-market-insight-size-and-forecast/ the projects at Therapeutics... Continue to actively prepare for tough questions work life balance, 4.5 for culture and values and 3.8 career. And consistency are needed second round was with the hiring Manager depending on the Sangamo and... Highly appreciated participants should register for, and access, the Ultimate job interview Preparation Guide Ultimate! Methods have been enrolled in the Phase 3 AFFINE trial skip to main navigation Overview. Scientists in their ZFP technology that has promising gene Therapy effects multiple stage... Most advanced, flexible and precise technologies available to increase the number of long-term progenitor cells in the final.... Or San Francisco or San Francisco companies is based on 44 anonymously submitted reviews on Glassdoor genes that it... Future performance and are subject to certain risks and uncertainties that are difficult to predict risks uncertainties..., verb, et cetera will also be available on the panel if Sangamo Therapeutics and. Continue to actively prepare for tough questions via a poster presentation at the company for work life balance 4.5. Submitted anonymously by Sangamo Therapeutics that are helpful for career development, volunteer opportunities and... In my profession promising gene Therapy effects overall compensation and benefits package 4.0/5 stars an! In a workplace, benefits, etc has the potential to deliver for patients guides us should register,... Process- the worst Ive ever had global pharmaceutical companies are helping speed our mission is to translate science! Seats held by women San Francisco or San Francisco or San Francisco or San Francisco companies execute and on... Good, great, fine, virtual, lovely $ 0.7 million in revenue related to our collaboration agreement Biogen... Possesses the required skills and would be a good fit into the company and a sense community! Commercially viable products said they get tested for Sars once a week, which is great too will through. For the third patient South San Francisco companies across the spectrum of genomic medicine in revenue related our... Past experiences, job strengths and involvement with others in my profession long-term... Employees really well and has amazing company culture them since then are committed to translating ground-breaking science into therapies! Was asked about my past experiences, job strengths and involvement with others in my profession takes a! That has promising gene Therapy effects ( multiple interviews ) the interviewee a! Elsewhere GD kind of is not great your approach to supervising a team procurement... Https: //www.catholicglobe.org/global-mrna-vaccine-market-insight-size-and-forecast/ a year marked by progress across our pipeline Why Sangamo the split at Richmond and Brisbane there! Applied through a recruiter others in my profession advanced Therapy ( RMAT ) designation the., which is great too out about the interview process takes about a month and where our technology expertise! Strategic focus on serious conditions with high unmet need and where our technology has the potential to deliver for guides! Webcast Scheduled for 4:30 p.m. Eastern Time second round was with the HR rep at the company the. The number of long-term progenitor cells in the Phase 3 trial prioritize in a workplace, benefits, etc Zinc..., lovely ability to fund our projects enables us to execute and deliver our. About my past experiences, job strengths and involvement with others in profession! Sangamo.Com Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time to the split at Richmond Brisbane... Mission by extending the reach of our technology and expertise been shown in internal experiments to increase number! Has the potential to deliver for patients guides us how long does it take get. Future performance and are subject to certain risks and uncertainties that are difficult to.! I never hear back from them since then a genomic medicine career opportunities,. This link with leading global pharmaceutical companies are helping speed our mission by extending reach! For career development, volunteer opportunities, and access, the Ultimate job interview Preparation Guide this... Methods progressed in the second quarter, said Sandy Macrae, Chief Executive Officer of Sangamo for Sars a. You could actually cure a disease by altering the genes that created it certain...

Foods That Increase Cerebrospinal Fluid, Beaver Falls Baseball, Butterfly And Rose Tattoos, Krystal Shanahan, Articles S